eMedicine Specialties > Hematology > Red Blood Cells and Disorders

Macrocytosis: Follow-up

Author: Wendy Brick, MD, Consulting Staff, Department of Internal Medicine, Division of Hematology and Oncology, Mecklenburg Medical Group
Coauthor(s): Russell Burgess, MD, Department of Internal Medicine, Division of Hematology/Oncology, East Carolina Internal Medicine
Contributor Information and Disclosures

Updated: Aug 29, 2009

Follow-up

Further Outpatient Care

  • Outpatient follow-up depends on the cause of the macrocytosis.

Inpatient & Outpatient Medications

  • Folate 1 mg/d may be prescribed in patients with folate deficiency.
  • Vitamin B-12 injections (100-1000 mcg IM per mo), continued indefinitely, may be prescribed.

Miscellaneous

Medicolegal Pitfalls

  • Failure to diagnose and treat the cause of the macrocytosis
 


More on Macrocytosis

Overview: Macrocytosis
Differential Diagnoses & Workup: Macrocytosis
Treatment & Medication: Macrocytosis
Follow-up: Macrocytosis
References
Further Reading

References

  1. Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Physician. Feb 1 2009;79(3):203-8. [Medline].

  2. Rumsey SE, Hokin B, Magin PJ, Pond D. Macrocytosis--an Australian general practice perspective. Aust Fam Physician. Jul 2007;36(7):571-2. [Medline][Full Text].

  3. Sternfeld T, Lorenz A, Schmid M, et al. Increased red cell corpuscular volume and hepatic mitochondrial function in NRTI-treated HIV infected patients. Curr HIV Res. May 2009;7(3):336-9. [Medline].

  4. Argento V, Roylance J, Skudlarska B, et al. Anemia prevalence in a home visit geriatric population. J Am Med Dir Assoc. Jul 2008;9(6):422-6. [Medline].

  5. Ganji V, Kafai MR. Hemoglobin and hematocrit values are higher and prevalence of anemia is lower in the post-folic acid fortification period than in the pre-folic acid fortification period in US adults. Am J Clin Nutr. Jan 2009;89(1):363-71. [Medline][Full Text].

  6. Ali G, Pecoud A, Decrey H, Verdon F. [Vitamin B 12 deficiency: early diagnosis in ambulatory care medicine]. Schweiz Med Wochenschr. Nov 7 1998;128(45):1763-71. [Medline].

  7. Atony AC. Megaloblasctic anemias. Hematology Basic Principles and Practice. 1995;2nd ed:552-581.

  8. Bessman JD, Banks D. Spurious macrocytosis, a common clue to erythrocyte cold agglutinins. Am J Clin Pathol. Dec 1980;74(6):797-800. [Medline].

  9. Breedveld FC, Bieger R, van Wermeskerken RK. The clinical significance of macrocytosis. Acta Med Scand. 1981;209(4):319-22. [Medline].

  10. Colon-Otero G, Menke D, Hook CC. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin North Am. May 1992;76(3):581-97. [Medline].

  11. Curtis D, Sparrow R, Brennan L, Van der Weyden MB. Elevated serum homocysteine as a predictor for vitamin B12 or folate deficiency. Eur J Haematol. Apr 1994;52(4):227-32. [Medline].

  12. Davenport J. Macrocytic anemia. Am Fam Physician. Jan 1996;53(1):155-62. [Medline].

  13. Ellaway C, Christodoulou J, Kamath R, et al. The association of protein-losing enteropathy with cobalamin C defect. J Inherit Metab Dis. Feb 1998;21(1):17-22. [Medline].

  14. Fernando OV, Grimsley EW. Prevalence of folate deficiency and macrocytosis in patients with and without alcohol-related illness. South Med J. Aug 1998;91(8):721-5. [Medline].

  15. Field EA, Speechley JA, Rugman FR, et al. Oral signs and symptoms in patients with undiagnosed vitamin B12 deficiency. J Oral Pathol Med. Nov 1995;24(10):468-70. [Medline].

  16. Grgic I, Kaistha BP, Paschen S, et al. Disruption of the Gardos channel (KCa3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly. Pflugers Arch. Jun 2009;458(2):291-302. [Medline].

  17. Karnad AB, Krozser-Hamati A. Pernicious anemia. Early identification to prevent permanent sequelae. Postgrad Med. Feb 1 1992;91(2):231-4, 237. [Medline].

  18. Lee RG. Anemia: A diagnostic strategy. Wintrobes Clinical Hematology. 1999;10th ed:911-920.

  19. Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol. Jun 1990;34(2):99-107. [Medline].

  20. Phekoo K, Williams Y, Schey SA, et al. Folate assays: serum or red cell?. J R Coll Physicians Lond. May-Jun 1997;31(3):291-5. [Medline].

  21. Rizeq M, Sinha SK, Zaman MN. Macrocytosis in elderly patients [letter; comment]. Age Ageing. May 1997;26(3):237-8. [Medline].

  22. Sechi LA, De Carli S, Catena C, et al. Benign familial macrocytosis. Clin Lab Haematol. Mar 1996;18(1):41-3. [Medline].

  23. Seppa K, Heinila K, Sillanaukee P, Saarni M. Evaluation of macrocytosis by general practitioners. J Stud Alcohol. Jan 1996;57(1):97-100. [Medline].

  24. Swain RA, St Clair L. The role of folic acid in deficiency states and prevention of disease. J Fam Pract. Feb 1997;44(2):138-44. [Medline].

  25. Thong KL, Hanley SA, McBride JA. Clinical significance of a high mean corpuscular volume in nonanemic patients. Can Med Assoc J. Oct 22 1977;117(8):909-10. [Medline].

  26. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. Dec 1989;32(12):1592-6. [Medline].

  27. Wu A, Chanarin I, Levi AJ. Macrocytosis of chronic alcoholism. Lancet. May 4 1974;1(7862):829-31. [Medline].

  28. Wymer A, Becker DM. Recognition and evaluation of red blood cell macrocytosis in the primary care setting. J Gen Intern Med. May-Jun 1990;5(3):192-7. [Medline].

  29. Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol. Jan 1999;36(1):35-46. [Medline].

Keywords

macrocytosis, macrocytes, megaloblasts, anemia, megaloblastic anemia, myelodysplastic anemia, myelophthisic anemia, aplastic anemia, acquired sideroblastic anemia, vitamin B-12 deficiency, folate deficiency, chronic alcoholism, alcoholism, accelerated erythropoiesis, chronic obstructive pulmonary disease, COPD, Lesch-Nyhan syndrome, deficient enzymes for folate metabolism, homocystinuria, liver disease, hypothyroidism

Contributor Information and Disclosures

Author

Wendy Brick, MD, Consulting Staff, Department of Internal Medicine, Division of Hematology and Oncology, Mecklenburg Medical Group
Wendy Brick, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, and American Society of Hematology
Disclosure: Nothing to disclose.

Coauthor(s)

Russell Burgess, MD, Department of Internal Medicine, Division of Hematology/Oncology, East Carolina Internal Medicine
Russell Burgess, MD is a member of the following medical societies: American College of Physicians and American Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Paul Schick, MD, Emeritus Professor, Department of Internal Medicine, Thomas Jefferson University Medical College; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital, Wynnewood, PA
Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Hematology, International Society on Thrombosis and Haemostasis, and New York Academy of Sciences
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Ronald A Sacher, MB, BCh, MD, FRCPC, Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center
Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Society of Hematology
Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.